Guidelines for pharmaceutical care of endocrine therapeutics for breast cancer(2023 edition).
10.3760/cma.j.cn112152-20230823-00097
- Collective Name:National Cancer Center;Oncology Specialty Pharmacist Subcommittee, Chinese Pharmacists Association
- Publication Type:Journal Article
- Keywords:
Aromatase inhibitors;
Breast neoplasms;
CDK4/6 inhibitors;
Endocrine therapy;
Pharmaceutical services
- MeSH:
Humans;
Female;
Breast Neoplasms/drug therapy*;
Aromatase Inhibitors/therapeutic use*;
Receptors, Estrogen
- From:
Chinese Journal of Oncology
2023;45(10):834-862
- CountryChina
- Language:Chinese
-
Abstract:
Endocrine therapy is one of the primary treatment methods for hormone receptor-positive breast cancer patients. As of June 1 2023, the National Medical Product Administration has approved 56 drugs related to endocrine therapy in patients with HR+ /HER-2- breast cancer (including generic drugs that have passed the consistency evaluation), including 44 endocrine drugs which can be categorized according to their mechanisms of action into selective estrogen receptor modulators, selective estrogen receptor down-regulators, aromatase inhibitors, luteinizing hormone-releasing hormone analogs, and progestogens and 12 targeted drugs for combined with endocrine therapy, including CDK4/6 inhibitors, mTOR inhibitors, and HDAC inhibitors. The different pharmacological characteristics, mechanisms of action, and long-term medication factors of breast cancer endocrine therapy-related drugs can directly affect patients' medication adherence and medication safety. To standardize the pharmaceutical care of endocrine therapy drugs for breast cancer and promote rational use in clinical settings, the Oncology Specialty Pharmacist Subcommittee, in conjunction with multidisciplinary experts nationwide, has developed the "Guidelines for pharmaceutical care of endocrine therapy drugs for breast cancer (2023 edition)". The guidelines is based on clinical evidence-based evidence, relevant regulations of pharmaceutical management, and pharmaceutical care practices. The Delphi method and expert interviews were used to formulate the guidelines. The GRADE approach was used for assessing the certainty of evidence. This guideline mainly focuses on endocrine therapy for HR+ /HER-2- breast cancer patients. Due to space constraints, HER-2 positive targeted drugs were not included in the guideline. It covers 6 dimensions and 22 key problems of pharmaceutical care in the whole process of drug therapy, providing a scientific basis for pharmacists to carry out pharmaceutical care of such drugs.
